Korro Bio (KRRO) Stock Crashes as Novo Nordisk Pauses Pact, KRRO‑110 Disappoints and 34% Layoffs Extend Cash Runway – What Investors Need to Know Today
Korro Bio shares plunged nearly 80% to around $6.60 in pre-market trading Thursday after the company reported mixed early data from its lead RNA-editing program, KRRO‑110, and announced layoffs, a pipeline shift, and a year-long pause in its Novo Nordisk partnership. The Phase 1/2a trial showed KRRO‑110 increased AAT protein but did not reach protective levels.
